<DOC>
	<DOCNO>NCT03001700</DOCNO>
	<brief_summary>To assess preliminary safety efficacy Serranator™ Alto PTA Serration Balloon Catheter subject atherosclerotic peripheral artery disease superficial femoral popliteal artery .</brief_summary>
	<brief_title>PRospective Study TrEatment Atherosclerotic Lesions Superficial Femoral and/or Popliteal Arteries Using Serranator DevicE</brief_title>
	<detailed_description>Single Arm , prospective , OUS multi-center feasibility study enrol 30 subject superficial femoral popliteal lesion . The study capture acute angiographic data compare pre- Serranator™ inflation v post inflation effect . The study population consist subject claudication ischemic rest pain , de novo non-stented restenotic lesion femoropopliteal artery lesion length less equal 10 cm , total occlusion 6 cm length reference vessel diameter 4 mm 6 mm , inclusive .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>1 . Male female &gt; 18 year old . 2 . Women child bear potential must negative pregnancy test within 7 day index procedure . 3 . Subject subject 's legal representative inform nature study , agree participate comply followup visit sign consent form . 4 . Resting ABI &lt; 0.9 . 5 . Subject eligible standard surgical repair target limb necessary . 6 . Subject Rutherford Clinical Category 2,3 , 4 7 . Estimated life expectancy &gt; 1 year . Angiographic 1 . Lesion ( ) locate within SFA popliteal artery . 2 . Target lesion ( ) stenosis &gt; 70 % visual assessment . 3 . Reference vessel diameter 4.0mm 6.0mm , inclusive . 4 . One long multiple serial lesion 10 cm , ( total occlusion 6cm ) length cover single balloon . 5 . Denovo , nonstented restenotic lesion 6 . At least one knee artery patent ankle . 7 . Successful treatment iliac inflow stenosis target limb . Stenosis treat procedure use standard angioplasty stenting use atherectomy exclude . The inflow lesion ( ) must treat first , prior consideration treatment target lesion . Subject enrol inflow lesion ( ) treat result &lt; 30 % residual stenosis evidence embolization significant complication . 1 . Rutherford Clinical Category 1 , 5 6 . 2 . Previously implanted ipsilateral femoral popliteal stent . 3 . Evidence aneurysm acute thrombus target vessel . 4 . Subjects previous bypass surgery low target extremity . 5 . Planned major amputation ( ankle ) either limb . 6 . Subject significant stenosis occlusion inflow tract successfully treat ( &gt; 30 % residual stenosis and/or significant complication procedure ) . 7 . History open surgical procedure within past 30 day . 8 . Planned endovascular vascular surgery procedure within 14 day prior ATK procedure , except treat inflow vessel day procedure , within next 30 day ATK procedure target limb . 9 . Subject allergy contrast medium pretreated . 10 . Episode acute limb ischemia within past 30 day . 11 . Subject systemic infection positive blood cultures/ bacteremia within one week . 12 . Subject hypercoagulable disorder 13 . Subject antiplatelet , anticoagulant , thrombolytic therapy contraindicate . 14 . Myocardial infarction within 30 day prior enrollment . 15 . History stroke TIA within 90 day prior enrollment . 16 . Subject acute chronic renal disease ( e.g. , measure serum creatinine &gt; 2.5 mg/dL &gt; 220 umol/L ) . 17 . Subject pregnant breastfeeding . 18 . Subject participate another research study device , medication , could , opinion investigator , affect result study . 19 . Subject medical , social psychological problem opinion investigator would preclude receive treatment procedure participate evaluation pre posttreatment . 20 . Thrombolysis target vessel within 72 hour prior index procedure , complete resolution thrombus achieve . 21 . Known allergy antiplatelet agent , aspirin , heparin . 22 . History neutropenia , coagulopathy , thrombocytopenia unexplained consider risk reoccurrence . 23 . Platelet count less 80,000/μL , 24 . Subject require general anesthesia procedure . 25 . Subject require dialysis . Angiographic 1 . Chronic Total Occlusions ( CTO ) &gt; 6cm length 2 . Acute Total Occlusions ; evidence acute thrombus formation angiography 3 . Severe calcification target lesion describe circumferential calcium &gt; 50 % lesion length . 4 . Subintimal access require 5 . Inability cross lesion guidewire 6 . Atherectomy target lesion , target artery inflow treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>